TR
T. Rowe Price Investment Management, Inc. disclosed a 8.2% stake in XENE
T. Rowe Price Investment Management, Inc. reported owning 8.2% of Xenon Pharmaceuticals Inc. (XENE) (7,905,757 shares) in a Schedule 13G filed Nov 6, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 6, 2026
- Source
- Schedule 13G